Patents by Inventor Marie-Pierre T. M. M. G De Bethune
Marie-Pierre T. M. M. G De Bethune has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200345733Abstract: The present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors. The compounds of the present invention inhibit the systemic infection of a human being with HIV, in particular, the present compounds prevent sexual HIV transmission in humans.Type: ApplicationFiled: July 16, 2020Publication date: November 5, 2020Inventors: Jens Marcel Van Roey, Marie-Pierre T.M.M.G. De Bethune, Paul Stoffels
-
Publication number: 20170100399Abstract: The present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors.Type: ApplicationFiled: December 23, 2016Publication date: April 13, 2017Inventors: Jens Marcel Van Roey, Marie-Pierre T.M.M.G. De Bethune, Paul Stoffels
-
Patent number: 8673551Abstract: The present invention relates to methods and means for the evaluation of HIV replicative capacity in a given environment. In particular, the invention provides a growth competition assay that can determine relative viral fitness using a recombinant tagged HIV-1 virus system. The methods rely on plasmid vectors, amplicons, primers and probes, and the generation of replication-competent viruses therefrom. Said methods and materials may find use in multiple fields including diagnostics, drug screening, pharmacogenetics and drug development.Type: GrantFiled: December 7, 2006Date of Patent: March 18, 2014Assignees: Speedx Pty Ltd., Janssen R&D IrelandInventors: Laurence Tatiana Rimsky, Inky Paul Madeleine De Baere, Bart Anna Julien Maes, Marie-Pierre T. M. M. G. De Bethune, Guenter Kraus, Elisa Mokany, Alison Velyian Todd
-
Patent number: 8592161Abstract: The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis.Type: GrantFiled: December 20, 2006Date of Patent: November 26, 2013Assignee: Janssen R&D IrelandInventors: Sandra De Meyer, Hilde Azijn, Marie-Pierre T. M. M. G. De Bethune
-
Patent number: 8076062Abstract: The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis.Type: GrantFiled: October 30, 2008Date of Patent: December 13, 2011Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Hilde Azijn, Marie-Pierre T. M. M. G De Bethune, Johan Hendrika Jozef Vingerhoets
-
Patent number: 8036861Abstract: The present invention relates to methods and means for determining the replication rate of a viral population. More specifically, the invention provides methods and means for determining the replication rate of a viral population by performing a linear regression on signal data generated by cells infected with dilutions of the viral population. The methods are useful for monitoring the progression of diseases associated with viruses, identifying effective drug regimens for the treatment of viral infections, and identifying and determining the biological effectiveness of potential therapeutic compounds.Type: GrantFiled: October 13, 2006Date of Patent: October 11, 2011Assignee: Tibotec PharmaceuticalsInventors: Laurence Tatiana Rimsky, Herwig Gaston Emiel Van Marck, Marie-Pierre T. M. M. G. De Bethune, Lee Terry Bacheler
-
Publication number: 20110165093Abstract: The present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors. The compounds of the present invention inhibit the systemic infection of a human being with HIV, in particular, the present compounds prevent sexual HIV transmission in humans.Type: ApplicationFiled: March 8, 2011Publication date: July 7, 2011Applicant: TIBOTEC PHARMACEUTICALS LTD.Inventors: Jens (Marcel) Van Roey, Marie-Pierre T.M.M.G. De Bethune, Paul Stoffels
-
Patent number: 7935710Abstract: The present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors. The compounds of the present invention inhibit the systemic infection of a human being with HIV, in particular, the present compounds prevent sexual HIV transmission in humans.Type: GrantFiled: May 13, 2003Date of Patent: May 3, 2011Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Jens Marcel Van Roey, Marie-Pierre T.M. M. G. De Bethune, Paul Stoffels
-
Patent number: 7863306Abstract: The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(?O)—, —O—C(?O)—, —NR8—C(?O)—, —O—C1-6alkanediyl-C(?O)—, —NR8—C1-6alkanediyl-C(?O)—, —S(?O)2—, —O—S(?O)2—, —NR8—S(?O)2; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or arylC1-4alkyl; R4 is H, C1-4alkylOC(?O), carboxyl, aminoC(?O), mono- or di(C1-4alkyl)aminoC(?O), C3-7cycloalkyl, C2-6alkenyl, C2-6alkynyl or optionally substituted C1-6alkyl; R5 and R6 are H or C1-6alkyl. It further relates to their use as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them.Type: GrantFiled: October 7, 2009Date of Patent: January 4, 2011Assignee: Tibotec Pharmaceuticals LtdInventors: Dominique Louis Nestor Ghislain Surleraux, Sandrine Marie Helene Vendeville, Wim Gaston Verschueren, Marie-Pierre T. M. M. G. De Bethune, Herman Augustinus De Kock, Abdellah Tahri
-
Publication number: 20100035229Abstract: The present invention relates to methods and means for the evaluation of HIV replicative capacity in a given environment. In particular, the invention provides a growth competition assay that can determine relative viral fitness using a recombinant tagged HIV-1 virus system. The methods rely on plasmid vectors, amplicons, primers and probes, and the generation of replication-competent viruses therefrom. Said methods and materials may find use in multiple fields including diagnostics, drug screening, pharmacogenetics and drug development.Type: ApplicationFiled: December 7, 2006Publication date: February 11, 2010Inventors: Laurence Tatiana Rimsky, Inky Paul Madeleine De Baere, Bart Anna Julien Maes, Marie-Pierre T.M.M.G. De Bethune, Guenter Kraus, Elisa Mokany, Alison Velyian Todd
-
Publication number: 20100029632Abstract: The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(?O)—, —O—C(?O)—, —NR8—C(?O)—, —O—C1-6alkanediyl-C(?O)—, —NR8—C1-6alkanediyl-C(?O)—, —S(?O)2—, —O—S(?O)2—, —NR8—S(?O)2; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or arylC1-4alkyl; R4 is H, C1-4alkylOC(?O), carboxyl, aminoC(?O), mono- or di(C1-4alkyl)aminoC(?O), C3-7cycloalkyl, C2-6alkenyl, C2-6alkynyl or optionally substituted C1-6alkyl; R5 and R6 are H or C1-6alkyl. It further relates to their use as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them.Type: ApplicationFiled: October 7, 2009Publication date: February 4, 2010Inventors: Dominique Louis Nestor Ghislain SURLERAUX, Sandrine Marie Helene Vendeville, Wim Gaston Verschueren, Marie-Pierre T.M.M.G. De Bethune, Herman Augustinus De Kock, Abdellah Tahri
-
Publication number: 20100009341Abstract: The present invention relates to methods and means for the evaluation of HIV treatment. In particular, molecular events at the HIV gag and protease proteins and their effect on therapeutic efficacy of drugs are determined The methods rely on providing HIV gag and protease nucleic acid material and evaluating a treatment either through genotyping or phenotyping. Said method may find use in multiple fields including diagnostics, drug screening, pharmacogenetics and drug development.Type: ApplicationFiled: April 13, 2007Publication date: January 14, 2010Inventors: Inky Paul Madeleine De Baere, Guenter Kraus, Laurence Tatiana Ramsky, Bart Anna Julien Maes, Hilde Azijn, Marie-Pierre T.M.M.G. De Bethune
-
Patent number: 7622490Abstract: The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7 cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(?O)—, —O—C(?O)—, —NR8—C(?O)—, —C1-6alkanediyl-C(?O)—, —NR8—C1-6alkanediyl-C(?O)—, —S(?O)2—, —O—S(?O)2—, —NR9-S(?O)2; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or arylC1-4alkyl; R4 is H, C1-4alkylOC(?O), carboxyl, aminoC(?O), mono- or di(C1-4alkyl)aminoC(?O), C3-7 cycloalkyl, C2-6alkenyl, C2-6alkynyl or optionally substituted C1-6alkyl; R5 and R6 are H or C1-6alkyl. It further relates to their use as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them.Type: GrantFiled: May 10, 2002Date of Patent: November 24, 2009Assignee: Tibotec Pharmaceuticals, Ltd.Inventors: Dominique Louis Nestor Ghislain Surleraux, Sandrine Marie Helene Vendeville, Wim Gaston Verschueren, Marie-Pierre T. M. M. G De Bethune, Herman Augustinus De Kock, Abdellah Tahri
-
Patent number: 7595334Abstract: The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(?O)—, —O—C(?O)—, —NR8—C(?O)—, —O—C1-6alkanediyl-C(?O)—, —NR8—C1-6alkanediyl-C(?O)—, —S(?O)2—, —O—S(?O)2—, —NR8—S(?O)2; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or arylC1-4alkyl; R4 is H, C1-4alkylOC(?O), carboxyl, aminoC(?O), mono- or di(C1-4alkyl)aminoC(?O), C3-7cycloalkyl, C2-6alkenyl, C2-6alkynyl or optionally substituted C1-6alkyl; A is C1-6alkanediyl, —C(?O)—, —C(?S)—, —S(?O)2—, C1-6alkanediyl-C(?O)—, C1-6alkanediyl-C(?S)— or C1-6alkanediyl-S(?O)2—; R5 is H, OH, C1-6alkyl, Het1C1-6alkyl, Het2C1-6alkyl, optionally substituted aminoC1-6alkyl; R6 is C1-6alkylO, Het1, Het1O, Het2, Het2O, aryl, arylO, C1-6Type: GrantFiled: January 23, 2007Date of Patent: September 29, 2009Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Dominique Louis Nestor Ghislain Surleraux, Sandrine Marie Helene Vendeville, Wim Gaston Verschueren, Marie-Pierre T. M. M. G. De Bethune, Herman Augustinus De Kock, Abdellah Tahri, Montserrat Erra Solà
-
Publication number: 20090061420Abstract: The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e.Type: ApplicationFiled: October 30, 2008Publication date: March 5, 2009Inventors: Hilde AZIJN, Marie-Pierre T.M.M.G. De Bethune, Johan Hendrika Jozef Vingerhoets
-
Patent number: 7473524Abstract: The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis.Type: GrantFiled: June 30, 2003Date of Patent: January 6, 2009Inventors: Hilde Azijn, Marie-Pierre T. M. M. G De Bethune, Johan Hendrika Jozef Vingerhoets
-
Patent number: 7429677Abstract: The present invention concerns a compound having the formula (I) a N-oxide form, a stereochemical isomer, racemic mixture, salt, prodrug, ester or metabolite thereof. It further relates to processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present entry inhibitors with anti-retroviral agents. It further relates to their use in assays as reference compounds or as reagents. The compounds of the present invention are useful for preventing or treating infection by HIV and for treating AIDS.Type: GrantFiled: March 11, 2003Date of Patent: September 30, 2008Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Marie-Pierre T. M. M. G De Bethune, Sandra De Meyer, Kurt Hertogs, Rong Jian Lu, Lieve Emma Jan Michiels, Abdellah Tahri, Dong Xie, Michael Eissenstat
-
Publication number: 20080220412Abstract: The present invention relates to methods and means for determining the replication rate of a viral population. More specifically, the invention provides methods and means for determining the replication rate of a viral population by performing a linear regression on signal data generated by cells infected with dilutions of the viral population. The methods are useful for monitoring the progression of diseases associated with viruses, identifying effective drug regimens for the treatment of viral infections, and identifying and determining the biological effectiveness of potential therapeutic compounds.Type: ApplicationFiled: October 13, 2006Publication date: September 11, 2008Inventors: Laurence Tatiana Rimsky, Herwig Gaston Emiel Van Marck, Marie-Pierre T.M.M.G. De Bethune, Lee Terry Bacheler
-
Patent number: 7244752Abstract: The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(?O)—, —O—C(?O)—, —NR8—C(?O)—, —O—C1-6alkanediyl-C(?O)—, —NR8—C1-6alkanediyl-C(?O)—, —S(?O)2—, —O—S(?O)2—, —NR8—S(?O)2; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or arylC1-4alkyl; R4 is H, C1-4alkylOC(?O), carboxyl, aminoC(?O), mono- or di(C1-4alkyl)aminoC(?O), C3-7cycloalkyl, C2-6alkenyl, C2-6alkynyl or optionally substituted C1-6alkyl; A is C1-6alkanediyl, —C(?O)—, —C(?S)—, —S(?O)2—, C1-6alkanediyl-C(?O)—, C1-6alkanediyl-C(?S)— or C1-6alkanediyl-S(?O)2—; R5 is H, OH, C1-6alkyl, Het1C1-6alkyl, Het2C1-6alkyl, optionally substituted aminoC1-6alkyl; R6 is C1-6alkylO, Het1, Het1O, Het2, Het2O, aryl, arylO, C1-6Type: GrantFiled: April 9, 2002Date of Patent: July 17, 2007Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Dominique Louis Nestor Ghislain Surleraux, Sandrine Marie Helene Vendeville, Wim Gaston Verschueren, Marie-Pierre T. M. M. G. De Bethune, Herman Augustinus De Kock, Abdellah Tahri, Montserrat Erra Solà
-
Patent number: 7217506Abstract: The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis.Type: GrantFiled: June 30, 2003Date of Patent: May 15, 2007Inventors: Sandra De Meyer, Hilde Azijn, Marie-Pierre T. M. M. G De Bethune